United Therapeutics (UTHR) Liabilities and Shareholders Equity (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $6.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 13.3% year-over-year to $6.7 billion; the trailing twelve-month figure through Mar 2026 stood at $29.9 billion (up 36.73% YoY), and the FY2025 full-year result was $7.9 billion, up 7.01% from the prior year.
• Liabilities and Shareholders Equity slipped to $6.7 billion in Q1 2026, from $7.9 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $7.9 billion in Q2 2025 to a low of $2.6 million in Q3 2024.
• A 5-year average of $6.4 billion and a median of $6.7 billion in 2026 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slumped 99.96% in 2024 and surged 282634.62% in 2025, its largest moves.
• Tracing UTHR's Liabilities and Shareholders Equity over 5 years: stood at $6.0 billion in 2022, then climbed by 18.57% to $7.2 billion in 2023, then rose by 2.75% to $7.4 billion in 2024, then climbed by 7.01% to $7.9 billion in 2025, then decreased by 14.79% to $6.7 billion in 2026.
• Business Quant data shows UTHR's Liabilities and Shareholders Equity at $6.7 billion in Q1 2026, $7.9 billion in Q4 2025, and $7.4 billion in Q3 2025.